If you are interested in participating in a DVTU study, please contact us to receive notices about current and future research studies.
|Dr. Swamy and Dr. Hughes are leading a study to assess the population pharmacokinetics of azithromycin and ertapenem administered as standard of care in pregnant women with failed labor leading to cesarean section.|
|Dr. Walter is leading the Duke site for a Phase 2 study to assess the safety, reactogenicity, and immunogenicity of an inactivated influenza A/H7N9 virus vaccine administered with or without AS03 adjuvant. Further information about this study can be found at clinicaltrials.gov.|
|Dr. Swamy and Dr. Tsalik are leading a study looking at procalcitonin (PCT) levels as a marker for bacterial versus viral lower respiratory tract infections. This study randomizes subjects with low PCT to azithromycin or placebo. Further information about this study can be found at clinicaltrials.gov.|
|Dr. Greenberg and Dr. Walter are leading a multicenter study to assess apnea following vaccination in premature infants receiving their standard of care two-month vaccinations. Furhtur informatiom about this study can be found at clinicaltrials.gov.|
|Dr. Schmader and Dr. Walter are leading a study to assess the safety and immunogenicity of adjuvanted versus high-dose inactivated flu vaccine in older adults. Further information about the trial can be found at clinicaltrials.gov.|
|Dr. Schmader is conducting a study to assess the population pharmacokinetics of meropenem and piperacillin-tazobactam administered in adults per clinical care. This study is looking at drug metabolism across age ranges.|
|Dr. Walter and Dr. Greenberg are conducting a study to assess the population pharmacokinetics of moxifloxacin administered to children per clinical care.|
|Dr. Walter is leading the Duke site for a study to evaluate shorter duration antibiotic therapy in children diagnosed with Community Acquired Pneumonia (CAP). Subjects will be randomized at day 5 to receive the full course of antibiotic therapy or placebo. Additional information about the study can be found at the link and at clinicaltrials.gov.|
|Dr. Swamy and Dr. Juel are leading a study to evaluate NTM-1633 in three dose cohorts (A: 0.033 mg/kg, B: 0.165 mg/kg, and C: 0.33 mg/kg). NTM-1633 is a mixture of three monoclonal antibodies designed to treat botulinum neurotoxin BoNT/E poisoning in adults. Further information about the trial can be found at clinicaltrials.gov.|
|Dr. Walter and Dr. Naggie are leading an observational study to assess the prevalence and outcomes of primary pulmonary coccidioidomycosis (also referred to as Valley Fever (VF) Pneumonia or acute onset valley fever) in persons presenting with community acquired pneumonia. Recruitment will take place at sites in areas where VF is endemic, including Arizona and California. Further information about the trial can be found at clinicaltrials.gov.|
Dr. Walter is leading the Duke site in a study to evaluate the safety of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) in children with asthma of varying levels of severity. The study is multicenter and will be enrolling 300 children. Subjects will be randomized to receive either LAIV4 or IIV4.
|Dr. Swamy and Dr. Dotters-Katz are leading a study to evaluate the safety of Flublok®, the first recombinant inactivated influenza vaccine (RIV), and Flulaval, quadrivalent-inactivated influenza vaccine (IIV4), in pregnant women. This study will also evaluate adverse outcomes in infants, local and systemic reactogenicity, vaccine-related adverse events and immunogenicity following maternal RIV.|
|Dr. Walter and Dr. Que are leading a study to assess the plasma and intrapulmonary pharmacokinetics of Fosfomycin (6 g), delivered intravenously over three doses, following a bronchoscopy. Duke will enroll 30 subjects for this study.|